Characterization of Rac and Cdc42 Activation in Chemoattractant-stimulated Human Neutrophils Using a Novel Assay for Active GTPases*

Valerie BenardDagger , Benjamin P. Bohl, and Gary M. Bokoch§

From the Departments of Immunology and Cell Biology, The Scripps Research Institute, La Jolla, California 92037

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A major function of Rac2 in neutrophils is the regulation of oxidant production important in bacterial killing. Rac and the related GTPase Cdc42 also regulate the dynamics of the actin cytoskeleton, necessary for leukocyte chemotaxis and phagocytosis of microorganisms. Although these GTPases appear to be critical downstream components of chemoattractant receptor signaling in human neutrophils, the pathways involved in direct control of Rac/Cdc42 activation remain to be determined. We describe an assay that measures the formation of Rac-GTP and Cdc42-GTP based on their specific binding to the p21-binding domain of p21-activated kinase 1. A p21-binding domain glutathione S-transferase fusion protein specifically binds Rac and Cdc42 in their GTP-bound forms both in vitro and in cell samples. Binding is selective for Rac and Cdc42 versus RhoA. Using this assay, we investigated Rac and Cdc42 activation in neutrophils and differentiated HL-60 cells. The chemoattractant fMet-Leu-Phe and the phorbol ester phorbol myristate acetate stimulate formation of Rac-GTP and Cdc42-GTP with distinct time courses that parallel cell activation. We also show that the signaling pathways leading to Rac and Cdc42 activation in HL-60 cells involve G proteins sensitive to pertussis toxin, as well as tyrosine kinase and phosphatidylinositol 3-kinase activities.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Small GTPases of the Ras superfamily serve as key regulators in the control of intracellular signaling pathways. GTPases regulate molecular events by cycling from the inactive GDP-bound state to active GTP-bound forms. This GDP/GTP cycle is regulated by the interaction of the GTPases with guanine nucleotide exchange factors (GEFs),1 GDP dissociation inhibitors, and GTPase-activating proteins (GAPs), presumably under the control of signaling events initiated by cell-surface receptors (1). The activated GTPases interact with specific target proteins that serve as effectors to regulate downstream signaling cascades. The Rho GTPase subfamily, which consists of the closely related GTPases Rho, Rac, and Cdc42, has been implicated in the regulation of diverse cellular functions, including actin cytoskeletal dynamics, oxidant generation, transformation, membrane trafficking, apoptosis, transcription, and cell cycle control (2-5).

Polymorphonuclear neutrophils are circulating cells that can be rapidly activated in response to inflammatory signals to adhere and migrate through the extracellular matrix to sites of infection and/or inflammation. At these sites, bacteria are phagocytized and killed through the secretion of granules and oxidants. Many studies indicate that small GTPases are involved at various levels to regulate the cellular functions involved in the inflammatory process (1, 6). The first identified biological activity of Rac was regulation of oxidant production by the phagocyte NADPH oxidase (3, 7, 8). This function has been confirmed through studies utilizing cell-free systems (9, 10), as well as intact cells (11), and in a transgenic model (12). Rac2 appears to be a required NADPH oxidase component in human neutrophils, and there is evidence to implicate direct interactions with both p67phox (13) and the cytochrome b558 (14, 15) oxidase proteins. More recent work has established that Rho GTPases control leukocyte cytoskeletal dynamics as well. Cdc42 induces actin polymerization in neutrophil extracts (16), and Rho, Rac, and Cdc42 have been implicated in the migratory responses of leukocytes to chemoattractant stimuli (17, 18) as well as in the phagocytic process (19, 20). Moreover, Rho, Rac, and Cdc42 are also involved in a variety of leukocyte signaling pathways, including activation of phospholipase D (21, 22), reviewed in Ref. 23. Whereas activation of the Rho GTPases is clearly critical for controlling the inflammatory responses of human leukocytes, the upstream signals and regulatory proteins controlling Rho family GTPase activation in these cells remain largely unknown.

Among the Rho GTPase targets identified in the neutrophil, the p21-activated kinases (PAK1 and -2) were initially found to be activated after fMet-Leu-Phe stimulation (24). Binding of Rac- or Cdc42-GTP leads to PAK autophosphorylation and activation of the ability to phosphorylate exogenous substrates on serine and/or threonine residues (25). Substrates for PAK in human neutrophils may include the p47phox and p67phox NADPH oxidase components (24, 26). Rac and Cdc42 activate PAK through binding to the p21-binding domain (PBD). This sequence, located in the N-terminal regulatory part of the protein, contains a highly conserved 14-amino acid CRIB domain (amino acids 74-88) found in many proteins interacting with Rac- or Cdc42-GTP (27). Whereas the minimal CRIB domain is sufficient for the binding of Rac and Cdc42, a larger sequence is required for high affinity interaction (amino acids 67-150) (28, 29) and effective activation by GTPases (30).

We have used the PBD domain of PAK1 as a probe to specifically isolate the active forms of Rac and Cdc42 from human neutrophil samples. Activation of Rac2 and Cdc42 by the chemoattractant fMet-Leu-Phe and the general stimulus phorbol myristate acetate (PMA) occurs with distinct time courses that parallel cellular activation by these agents. We have also investigated the signaling pathways involved in Rac2 and Cdc42 activation by chemoattractant, including the participation of heterotrimeric G proteins, tyrosine kinases, and PI 3-kinase. The PAK PBD-based assay provides a simple and direct means to determine Rac and Cdc42 activation in cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Biological Materials-- Human neutrophils of 90-95% purity were prepared from freshly drawn blood from healthy volunteers collected in acid/citrate/dextrose. Neutrophils were purified by dextran sedimentation, hypotonic lysis of erythrocytes, and centrifugation through Ficoll-Paque, as described (31). The cells were diisopropyl fluorophosphate-treated, washed with 0.9% NaCl, and finally resuspended in Krebs-Ringer Hepes buffer containing 5.5 mM glucose (KRHG) for experiments.

Human pro-myelocytic leukemic HL-60 cells stably transfected to express the fMLP receptor (32) were maintained in a selective RPMI 1640 medium containing 10% fetal bovine serum and 0.8 mg/ml geneticin. The cells (0.8 to 1.0 × 106/ml) were differentiated into neutrophil-like cells by treatment with 1.4% Me2SO for 5 days.

Production and Isolation of Recombinant Proteins-- The cDNA of the GTPase-binding domain (PBD) from human PAK1 (amino acids 67-150) or from Schizosaccharomyces pombe PAK1 (amino acids 135-227) was cloned into the bacterial expression vector pGEX-4T3 and pGEX-2T, respectively, and was expressed in Escherichia coli as a fusion protein with glutathione S-transferase. The purified fusion proteins were isolated from glutathione-Sepharose beads with 10 mM reduced glutathione and stored at -80 °C in 25 mM Tris-HCl, pH 7.5, 0.2 M DTT, 1 mM MgCl2, and 5% glycerol.

Transfection of BHK Cells with Semliki Forest Virus-- The cDNA fragment encoding Rac2 wild type and Rac2 mutants Q61L and T17N were subcloned in the pSFV3 vector, and the recombinant virus was generated per Life Technologies, Inc. instruction manual. BHK (baby hamster kidney) cells were infected with virus in Glasgow minimum essential medium complete media (Life Technologies, Inc.) and allowed to grow 15 h before cell lysis in 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl2, 1 mM DTT, 0.1 mM EGTA, 100 mM NaCl, 1% Nonidet P-40, 5% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 1 mM orthovanadate.

Cell Pretreatments and Stimulation-- Cells (2 × 107/assay) were suspended in KRHG containing 1 mM Ca2+ and stimulated with 10-6 M fMLP (fMet-Leu-Phe) or 100 ng/ml PMA at 37 °C for the times indicated. In some experiments, cells were pretreated for 15 min at 37 °C with the following inhibitors, 100 µM genistein, 20 µM LY294002, 30 nM wortmannin, or for 24 h with 20 ng/ml pertussis toxin. At the appropriate time, cell activation was stopped by addition of an equal volume of 2× lysis buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 200 mM NaCl, 2% Nonidet P-40, 10% glycerol, 2 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml aprotinin, and 2 mM orthovanadate) in the presence of 8 µg of GST-PBD. Cell lysates were immediately placed at 4 °C and then clarified by low speed centrifugation at 4 °C.

Guanine Nucleotide Binding-- Recombinant GTPases, cytosolic GTPases, or cell lysates were incubated for 15 min at 30 °C in the presence of 10 mM EDTA and 100 µM GTPgamma S or 1 mM GDP to facilitate nucleotide exchange (33). The loading reaction was stopped by addition of 60 mM MgCl2.

Affinity Precipitation Using GST-PBD-- Recombinant or cytosolic GTPases and 8 µg of GST-PBD in a volume of 100 µl were incubated with 200 µl of binding buffer (25 mM Tris-HCl, pH 7.5, 1 mM DTT, 30 mM MgCl2, 40 mM NaCl, 0.5% Nonidet P-40), and 5 µl of glutathione-Sepharose 4B beads for 30 min (recombinant proteins) or 1 h (cell samples) at 4 °C. The bead pellet was then washed 3 times with 25 mM Tris-HCl, pH 7.5, 1 mM DTT, 30 mM MgCl2, 40 mM NaCl, 1% Nonidet P-40 and 2 times with the same buffer without Nonidet P-40. The bead pellet was finally suspended in 20 µl of Laemmli sample buffer. Proteins were separated by 12% SDS-PAGE, transferred to nitrocellulose membrane, and blotted for the appropriate GTPase using specific R786 (Rac2) and R785 (Rac1) antibodies (34), the Cdc42 polyclonal antibody from Santa Cruz Biotechnology (SC-87), and the RhoA monoclonal from Santa Cruz Biotechnology (SC-418). Immunoblots were detected with the SuperSignal chemiluminescence kit from Pierce and/or by alkaline phosphatase detection. Signals detected were within the linear range of the detection method using Kodak X-Omat AR film, as determined with recombinant Rac and Cdc42 standards (1-64 ng). Equivalent experimental results were obtained using the human PAK PBD and the S. pombe PAK PBD.

In Vitro GTPase Binding Studies-- Recombinant Rac1 was loaded with [35S]GTPgamma S or [3H]GDP as described (33), and then free nucleotides were removed by centrifugation in a Centriplus 10 filtration unit. For saturation binding experiments, 10 pmol of Rac1 [35S]GTPgamma S was incubated with increasing amounts of GST-PBD and 5 µl of glutathione-Sepharose beads. For competition binding experiments, 200 pmol of GST-PBD was incubated with 10 pmol of Rac1-[35S]GTPgamma S and increasing amount of Rac1 loaded with unlabeled GTPgamma S added either at time 0 or 30 and 60 min after the start of the incubation. After 1 h at 4 °C, the beads were washed 5 times with wash buffer (25 mM Tris-HCl, pH 7.5, 1 mM DTT, 30 mM MgCl2, 40 mM NaCl, 1 mg/ml bovine serum albumin), and the radioactivity bound to the beads was quantified by liquid scintillation counting.

Intrinsic GTP Hydrolysis Activity-- Recombinant Rac1 or Cdc42 (50 ng) were preloaded with [gamma -32P]GTP or [35S]GTPgamma S, and GTP hydrolysis was determined in the presence or absence of 4 µg of GST-PBD as described (35).

NADPH Oxidase Activity-- Superoxide generation was determined by reduction of cytochrome c as in Ref. 36.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Development of a PBD-based Assay of Rac/Cdc42 Activation

Specificity of the Interaction between Recombinant Rac and GST-PBD-- The PAK protein exhibits a selective affinity for the GTP-bound form of Rac or Cdc42 (25). We first verified that this specificity for the active conformation of the GTPases is maintained in the isolated PAK GST-PBD fusion protein. Purified GST-PBD was used as a probe in an affinity precipitation assay with different nucleotide-bound forms of recombinant Rac1. Fig. 1a shows that GST-PBD effectively interacts with the active GTPgamma S-bound form of the GTPase. There was little or no interaction with the inactive GDP-bound form. We verified that Rac1-GTPgamma S did not bind nonspecifically to GST beads or to glutathione-Sepharose beads alone. To confirm this result, we investigated the interaction of GST-PBD with overexpressed cytosolic GTPases. BHK cells overexpressing Rac2 wild type, the constitutively GTP-bound active form (Q61L), or the GDP-bound (T17N) inactive form were lysed and used for the affinity precipitation assay (Fig. 1b). GST-PBD did not interact with wild type Rac2 loaded with GDP nor the T17N mutant. In contrast, GST-PBD effectively bound and precipitated the active forms of Rac2, including the wild type Rac2 when loaded with GTPgamma S and the Q61L mutant which is constitutively GTP-bound due to its inability to hydrolyze bound GTP. In each case, the unbound GTPases were recovered in the reaction medium. These results show that GST-PBD is interacting specifically with the active form of isolated recombinant or cellularly expressed GTPases.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 1.   Specificity and selectivity of the interaction between Rho GTPases and GST- PBD. a, recombinant Rac1 (100 ng, directly visualized in lane 1) was loaded with GTPgamma S and incubated with 10 µg of GST control beads (lane 2) or was loaded with GDP (lane 3) or GTPgamma S (lanes 4 and 5) and incubated with 10 µg of GST-PBD (lanes 3 and 4) and then precipitated with glutathione-Sepharose beads (lanes 2-5). b, BHK cells expressing the wild type form of Rac2 or the constitutively GTP-bound Q61L and constitutively GDP-bound T17N mutants were lysed and used for affinity precipitation with 10 µg GST-PBD, as per "Experimental Procedures." To confirm that we could detect Rac2 wild type, lysates expressing this protein were also loaded with GTPgamma S prior to the incubation with GST-PBD, as indicated (+). After precipitation with glutathione-Sepharose beads (P indicates the precipitate), an aliquot (1/20) of the proteins remaining in suspension (S) was loaded on the gel to visualize the remaining non-bound protein. c, neutrophil cytosol corresponding to 2 × 106 cell equivalents (visualized in lane 1 each panel) was loaded with GDP (lanes 2) or GTPgamma S (lanes 3) prior to affinity precipitation in the presence of 8 µg of GST-PBD on glutathione-Sepharose beads. After each binding reaction at 4 °C, the proteins bound to the beads (and a fraction of unbound protein, see panel b) were separated on SDS-PAGE, transferred onto nitrocellulose membrane, and blotted for the appropriate GTPase as indicated, followed by ECL detection. Representative results of four (a and c) or two (b) independent experiments are shown.

Selectivity of the Interaction-- It has previously been shown that the PAK1 binds Rac and Cdc42 but not Rho (24, 25). To determine if the GST-PBD domain behaves with the same selectivity, cytosolic fractions of neutrophils, known to express Rac1, Rac2, Cdc42, and RhoA, were loaded with GTPgamma S or GDP. The affinity precipitation assay with GST-PBD was performed, and the presence of each GTPase was assessed with specific antibodies. As shown in Fig. 1c, GST-PBD interacts with Rac1, Rac2, and Cdc42 but not Rho. The specificity observed with full-length PAK1 is thus maintained in the isolated PBD.

Interaction Studies-- In order to characterize the interaction of GST-PBD with the GTPase, we performed binding studies with recombinant GTPases loaded with labeled nucleotides. The amount of GST-PBD required to effectively complex with and pull down the GTPases was determined by loading Rac1 with [35S]GTPgamma S and incubating with increasing amounts of GST-PBD (Fig. 2a). Binding was saturable and required levels of GST-PBD at least 20 times the total amount of recombinant Rac1 to recover more than 90% of the GTPase, as expected by mass action. Experiments where GST-PBD was incubated with Rac1-[35S]GTPgamma S in the presence of increasing amounts of unlabeled Rac1-GTPgamma S demonstrated that the interaction was competitive (Fig. 2b). In contrast, the addition of Rac1-GDP was ineffective (not shown). We then performed the same experiment, but this time the unlabeled Rac1-GTPgamma S was added either 30 or 60 min after the initial binding of labeled Rac1-GTPgamma S to the GST-PBD. Measuring the stability of the first interaction, we observed that labeled Rac1 remained tightly bound to GST-PBD (Fig. 2b). These results indicate that the PBD-GTPase complex, once formed, is of high affinity and is stable. This interaction has been estimated to have a Kd of ~30 nM (28).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   Binding studies of GST-PBD with recombinant GTPases. a, saturation of binding. Recombinant Rac1 (20 pmol) was loaded with non-hydrolyzable [35S]GTPgamma S and incubated with increasing amount of GST-PBD, and then binding was analyzed as indicated under "Experimental Procedures." Results shown are the mean ± S.D. of 4-5 separate experiments. b, stability of binding. For competition binding experiments, 200 pmol of GST-PBD were incubated with 10 pmol of Rac1-[35S]GTPgamma S in the presence of increasing amounts of unlabeled Rac1-GTPgamma S. Unlabeled Rac1-GTPgamma S was either added simultaneously with the radiolabeled form (solid circles) or 30 (solid triangles) or 60 (open circles) min after prior incubation of GST-PBD with the labeled Rac1-[35S]GTPgamma S. After interaction for 30 min at 4 °C between Rac and GST-PBD, the affinity complex was precipitated with glutathione-Sepharose beads and washed, and the radioactivity bound to the bead pellet was counted. c, recombinant Cdc42 (50 ng) was loaded with [gamma -32P]GTP (solid lines) or [35S]GTPgamma S (dashed lines) and analyzed either in KRHG buffer or after addition to neutrophil cytosol, as indicated. Inhibition of the intrinsic GTP hydrolysis of Cdc42 by GST-PBD (solid lines) was measured by counting the amount of the [gamma -32P]GTP remaining associated with Cdc42 over a 20-min time course at 20 °C in the presence (open circles) or the absence (solid circles) of 4 µg of GST-PBD. Nucleotide dissociation was similarly assessed using [35S]GTPgamma S-loaded Cdc42 (dashed lines), and in the presence (open circle) or absence (solid circle) of GST-PBD. Values shown in b and c are the mean of three separate experiments.

It has been reported that both intrinsic and GAP-stimulated GTP hydrolysis are blocked when Rac or Cdc42 is bound to PAK (25, 28). Since GTP hydrolysis by endogenous GTPases can occur during affinity isolation with GST-PBD and potential GAP activity may be present in cellular samples, the inhibition of this loss of active GTPase would be desirable for an assay to detect GTPase activation. To assess the potential effect of the GST-PBD to inhibit GTP hydrolysis in cellular samples, recombinant Cdc42 loaded with the hydrolyzable nucleotide [gamma -32P]GTP was added to neutrophil cytosol, and GTP hydrolysis was determined in the presence or absence of GST-PBD. The presence of GST-PBD was observed to decrease, but not totally prevent, GTP hydrolysis by Cdc42 (Fig. 2c). To confirm that we were measuring GTP hydrolysis and not nucleotide dissociation, the same experiment was performed with Cdc42 loaded with the poorly hydrolyzable nucleotide [35S]GTPgamma S. We observed that the amount of [35S]GTPgamma S remaining bound to the Cdc42 only decreased very slowly, indicating that appreciable dissociation was not taking place under the conditions of the binding assay. The lack of complete inhibition of GTP hydrolysis by the PBD suggests that, in order to avoid loss of GTP-bound GTPase due to hydrolysis, the GST-PBD incubation period should be kept short. This is balanced, however, by the time needed for association of the GTP-GTPase with the PBD protein; 30-min to 1-h incubations appear to give optimal results.

Rac and Cdc42 Activation in fMLP-stimulated Leukocytes

Neutrophils were stimulated with 1 µM fMLP or 100 ng/ml PMA, and activation of Rac and Cdc42 was investigated using the GST-PBD binding assay. Stimulation by fMLP led to a rapid and transient activation of both Rac2 and Cdc42. Analysis at various times after stimulation with fMLP showed that activation of Rac2 and Cdc42 peaked between 30 s to 1 min, followed by a decrease in levels of active GTPase (Fig. 3a). Stimulation with PMA also induced Rac2 and Cdc42 activation, but the formation of GTP-GTPase was slower, reaching the maximal level of activation at 5 min after stimulation. The relative amount of activated GTPase formed with each stimulus was compared with the total amount of activable GTPases present in the cell lysates, as determined by preloading the total GTPase in the sample with GTPgamma S (leftmost panels in Fig. 3, a and b). We estimated that ~2 (fMLP) to ~5% (PMA) of Rac2 and ~5 (fMLP) to 10% (PMA) of Cdc42 are activated out of the total available cellular GTPase pool.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Rac2 and Cdc42 activation in human neutrophil and HL-60 cells after fMLP or PMA stimulation. a, time course of Rac2 and Cdc42 activation in human neutrophils. Neutrophils (2 × 107 cells/ml) were stimulated with 1 µM fMLP or 100 ng/ml PMA in KRHG/Ca2+ buffer at 37 °C. At appropriate times, activation was stopped by addition of ice-cold 2× lysis buffer. The resulting cell lysate was clarified and used for the affinity precipitation assay for 1 h at 4 °C in the presence of 8 µg of GST-PBD. Proteins bound to GST-PBD were separated on SDS-PAGE, transferred on nitrocellulose membrane, and blotted for Rac2 or Cdc42, followed by ECL detection. Representative results of eight (fMLP) and two (PMA) independent experiments are shown. Results quantified by densitometry are shown below each panel. The small inset at the left of each experiment shows the total signal detected using cytosol pre-exchanged with either GTPgamma S or GDP, as described under "Experimental Procedures." b, time course of Rac2 and Cdc42 activation in HL-60 cells. Granulocyte-like Me2SO-differentiated HL-60 (2 × 107 cells/ml) were stimulated by 1 µM fMLP or 100 ng/ml PMA and treated as described above for neutrophils. Representative result of seven (fMLP) or two (PMA) independent experiments are shown. c, quantification of GTPase activation at early times. In order to evaluate the reproducibility of our determinations in different experiments using distinct neutrophil preparations, we quantified the PBD immunoblots by densitometry. The values obtained for Rac2 and Cdc42 activation at early times in human neutrophils and HL-60 cells were averaged after normalization of the 30-s values to an arbitrary value of 100. The results shown are the mean ± S.E. of n = 3-4 separate experiments using distinct donors (neutrophils).

Previous studies from our laboratory had used the stimulus-dependent translocation of Rac2 to the plasma membrane as a measure of GTPase activation in human neutrophils (34). Translocation of Rac2 in response to either fMLP or PMA occurs with an identical time course as does Rac2 activation determined with the PBD assay; in both cases this correlates well with activation of NADPH oxidase activity (not shown here, but see Ref. 34). Additionally, the amounts of Rac2 shown to translocate upon stimulation with fMLP or PMA were similar to the fraction that we could directly measure as being activated, suggesting that the assay was accurately measuring the level of GTP-Rac2 formed. Interestingly, however, whereas the formation of Rac2-GTP measured here was transient, peaking by 1 or 5 min, respectively, with fMLP and PMA, the translocated Rac2 remains membrane-associated for a much longer period (34). This suggests that once membrane-bound, the Rac2 may be stabilized in a protected complex with other NADPH oxidase components.

We observed a similar time course of GTPase activation in the promyelocytic cell line HL-60 differentiated into neutrophil-like cells (Fig. 3b). The time course of activation by fMLP and the relative fraction of active Rac2 and Cdc42 formed were essentially the same as in peripheral human neutrophils (Fig. 3a), suggesting that similar mechanisms of activation for Rac and Cdc42 may exist in this differentiated promyelocytic cell line. In contrast to fMLP, stimulation with PMA in HL-60 cells appeared to somewhat slower in stimulating the increase in active Rac and Cdc42, although peak activation was still observed by 5 min. Again, this correlated well with the kinetics of NADPH oxidase activation (not shown).

Analysis of GTPase activation in neutrophils and HL-60 cells at early times was difficult due to the rapidity of the response and because of the well known propensity of the leukocytes to become partially activated by contact with test tube surfaces. This surface-induced activation seemed to cause increases in the basal (unstimulated) levels of active Rac and Cdc42. Stimulation in response to fMLP at early times was therefore carefully analyzed by averaging the early time point data obtained from several separate experiments with different leukocyte preparations (Fig. 3c). Activation was clearly evident by 30 s and remained the same or slightly increased by 1 min.

Signaling Pathways Involved in Rac2 and Cdc42 Activation in HL-60 Cells

The fMLP receptor is known to couple to activation of neutrophil functional responses via a pertussis toxin-sensitive heterotrimeric Gi protein (37). Treatment of HL-60 cells with pertussis toxin effectively inhibited Rac2 activation (Fig. 4). The pathway leading to Rac/Cdc42 activation thus requires the initial coupling of the fMLP receptor to Gi and places the activation of these small GTPases downstream of the heterotrimeric G protein.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of Rac2 activation by pertussis toxin. Me2SO-differentiated HL-60 cells were cultured 24 h in the presence (+) or the absence (-) of 20 ng/ml pertussis toxin (PTX). Cells were then washed, resuspended in KRHG/Ca2+ buffer (2 × 107 cells/ml), and stimulated for 30 s with 1 µM fMLP. Cells were lysed by addition of ice-cold 2× lysis buffer, and the lysate was used for the affinity precipitation assay in the presence of 8 µg of GST-PBD, as indicated under "Experimental Procedures." Proteins bound to GST-PBD were separated on SDS-PAGE, transferred to nitrocellulose membrane, and blotted for Rac2, followed by alkaline phosphatase detection. Control lysates were loaded with GTPgamma S or GDP, as indicated. Figure is a representative result of four independent experiments.

The involvement of soluble tyrosine kinases in fMLP receptor signaling has been suggested by the ability of tyrosine kinase inhibitors to block fMLP-mediated cell activation, including the fMLP-induced membrane translocation of Rac2 (38). It has also been shown that fMLP receptor stimulation causes activation of the src-related kinase, Lyn, through an association with the Shc adaptor protein (39). We observed that treatment of HL-60 cells with 100 µM genistein prior to fMLP stimulation blocks Rac2 and Cdc42 activation (Fig. 5). These data directly indicate the involvement of tyrosine kinase activity in the pathway leading to Rac2 and Cdc42 activation.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 5.   Rac2 and Cdc42 activation in HL-60 cells stimulated with fMLP is blocked by tyrosine kinase and PI 3-kinase inhibitors. Me2SO-differentiated HL-60 cells suspended in KRHG/Ca2+ (2 × 107 cells/ml) were treated 15 min at 37 °C in the presence of Me2SO (as control) or the following inhibitors: 100 µM genistein, 20 µM LY294002, or 30 nM wortmannin. Cells were then stimulated with 1 µM fMLP at 37 °C for 1 min, and activation was stopped by the addition of ice-cold 2× lysis buffer. Cell lysate was used for the affinity precipitation assay in the presence of 8 µg of GST-PBD. Proteins bound to GST-PBD were separated on SDS-PAGE, transferred to nitrocellulose membrane, and blotted for Rac2 or Cdc42, followed by ECL detection. Values are the mean of three separate experiments; error bars represent standard deviation.

PI 3-kinase has been shown to be involved in an upstream signaling pathway required for Rac activation in fibroblasts (40). PI 3-kinase activity is also required for chemoattractant receptor signaling, as the specific PI 3-kinase inhibitors wortmannin and LY294002 are able to decrease superoxide production and many other neutrophil functions (41-44). The majority of the phosphatidylinositol 1,4,5-trisphosphate formed in human neutrophils requires a tyrosine kinase-linked pathway involving the classical forms of PI 3-kinase (45), although a G protein subunit-regulated enzyme may also be involved (46). In order to determine if PI 3-kinase activity was required for fMLP-induced Rac2 and Cdc42 activation in human neutrophils, we treated cells with 5-30 nM of wortmannin or 5-20 µM of LY294002 prior to stimulation with fMLP. Substantial, but not complete, inhibition of Rac or Cdc42 activation was observed with both inhibitors (Fig. 5). In each experiment, NADPH oxidase activity was measured and was found to be totally inhibited at the inhibitor concentrations utilized. Thus, both PI 3-kinase-regulated and independent mechanisms for Rac and Cdc42 activation may exist in human neutrophils.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Although roles for Rac and Cdc42 in human leukocyte function have been demonstrated, the ability of inflammatory mediators to stimulate the formation of Rac-GTP or Cdc42-GTP has not been previously established. By using a specific assay based on the GTPase-binding domain of PAK, we demonstrate the formation of GTP-Rac2 and GTP-Cdc42 in human neutrophils stimulated with the chemoattractant fMLP or the phorbol ester PMA. Activation of both Rac2 and Cdc42 in response to fMLP is rapid, peaking at 0.5 to 1 min. This time course corresponds well to the activation of the Rac- and Cdc42 effectors PAK1 and -2 in these cells (24), as well as to activation of the NADPH oxidase (34). The receptor-induced activation of Rac2 also correlates with the translocation of Rac2 to the plasma membrane, as previously reported (34). This translocation has been shown to require the formation of Rac2-GTP in vitro (47). An interesting difference observed was that while Rac2 activation was transient, the Rac2 protein itself appears to remain membrane-associated for longer periods. It is possible that we are only measuring that fraction of activated GTPase that remains accessible to the GST-PBD in our assay and that the membrane-associated Rac2 enters into a higher affinity complex with NADPH oxidase and/or other effectors. The formation of such a protected complex was previously suggested by the inability of addition of a Rac-GAP to inhibit oxidase activity once the membrane-associated complex was assembled (48). Alternatively, the Rac2 may remain membrane-associated even after conversion to the inactive GDP-form, suggesting cycling to the cytosol (via GDP dissociation inhibitors) may lag behind inactivation of the GTPase.

Quantitative comparison of the amount of Rac2 or Cdc42 which becomes PBD-associated versus the total level of GTPase present which can be loaded with GTP indicates only a fraction of the total becomes active in response to fMLP or PMA. Again, this conclusion is consistent with the previous observation that only a (similar) fraction of Rac2 translocates in response to stimulation with these agonists (34). The similarity of the relative amount of Rac activated as determined using the two separate methods suggests that the PBD assay is not seriously underestimating the amount of active GTPases formed. Certainly the results of Fig. 2c suggest that GTP hydrolysis during the assay could potentially cause some underestimation of the amount of GTP-GTPase detected. Furthermore, it is likely that some portion of the GTP-Rac or Cdc42 formed is bound by other effector targets prior to association with the added PBD domain. We have attempted to minimize these potential factors by addition of the PBD during the cell lysis step and by maintaining samples on ice. However, one can expect that the assay will only be semi-quantitative, reflecting accurately the time course of activation but not absolute levels of GTP-GTPase.

The activation of Rho family GTPases by cellular stimuli is thought to most likely be due to the activation of guanine nucleotide exchange factors (GEFs) (47). Since the PBD assay enabled us to measure directly the chemoattractant- and phorbol ester-stimulated formation of Rac2-GTP and Cdc42-GTP, we used pharmacologic agents to investigate the signaling components necessary for GTPase activation. Rac2 activation in response to fMLP was effectively inhibited by treatment with pertussis toxin, indicating that the GTP exchange reaction is initiated downstream of the heterotrimeric G protein coupled to this receptor. The activation was also sensitive to the tyrosine kinase inhibitor genistein and, partially, to PI 3-kinase inhibitors, indicating the need for tyrosine kinase activity and PI 3-kinase activity upstream of the putative GEF(s). Although this could reflect the activity of multiple GEFs regulated by each pathway independently, it is of interest that both tyrosine phosphorylation and phosphatidylinositol 1,4,5-trisphosphate binding are necessary components for activation of the Vav Rac/Cdc42 exchange factor (49, 50). As Vav is expressed only in myeloid cells (51), it becomes a prime candidate for mediating Rac and Cdc42 activation by the N-formyl peptide receptor.

In conclusion, we have developed and characterized a specific assay for the formation of GTP-Rac and GTP-Cdc42 in cells. By using this assay, we demonstrate the activation of Rac2 and, for the first time, Cdc42 in human neutrophils in response to chemoattractant receptor activation and phorbol ester stimulation. The similarities in the activation kinetics of both GTPases and their similar pharmacologic inhibition profile suggest that their activation may be catalyzed by the same GEF. In addition, because we show Cdc42 becomes activated rapidly, with kinetics correlating with those of leukocyte functional responses, Cdc42 can potentially be involved in regulation of some of these responses. Identification of the GEF(s) responsible for chemoattractant receptor signaling to Rac and Cdc42 remains an important goal for future investigations.

    ACKNOWLEDGEMENTS

We thank Jon Chernoff (Fox Chase Cancer Center) for providing the S. pombe PAK PBD; Luraynne Sanders for providing samples of virally expressed Rac GTPases; Eric Prossnitz (University of New Mexico) for the fMLP receptor-expressing HL-60 cell line; Frank Zenke and Wesley Scott for providing technical assistance; C. C. King for thoughtful suggestions; and Antonette Lestelle for editorial assistance. We acknowledge the GCRC facilities for use of blood-drawing services provided by U. S. Public Health Service Grant M01 RR00833 at The Scripps Research Institute.

    FOOTNOTES

* This work was supported in part by U. S. Public Health Service Grants GM39434 and GM44428 (to G. M. B.). This is manuscript number 12082-IMM from the Scripps Research Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a fellowship from the Association Pour la Researche Sur Le Cancer during the tenure of this work and is currently a recipient of a National Arthritis Foundation Postdoctoral Fellowship.

§ To whom correspondence should be addressed: Depts. of Immunology and Cell Biology, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-784-8217; Fax: 619-784-8218; E-mail: bokoch{at}scripps.edu.

    ABBREVIATIONS

The abbreviations used are: GEF, guanine nucleotide exchange factors; PAK, p21-activated kinase; PBD, p21-binding domain; GST, glutathione S-transferase; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; PI 3-kinase, phosphatidylinositol 3-kinase; GAP, GTPase-activating protein(s); PMA, phorbol myristate acetate; fMLP, fMet-Leu-Phe; DTT, dithiothreitol; BHK, baby hamster kidney; PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Bokoch, G. M. (1995) Blood 86, 1649-1660[Free Full Text]
  2. Hall, A. (1998) Science 279, 509-514[Abstract/Free Full Text]
  3. Bokoch, G. M. (1995) Trends Cell Biol. 5, 109-113[CrossRef]
  4. Zigmond, S. H. (1996) Curr. Opin. Cell Biol. 8, 66-73[CrossRef][Medline] [Order article via Infotrieve]
  5. Van Aelst, L., and D'Souza-Schorey, C. (1997) Genes Dev. 11, 2295-2322[Free Full Text]
  6. Quinn, M. T. (1995) J. Leukocyte Biol. 58, 263-276[Abstract]
  7. Knaus, U. G., Heyworth, P. G., Evans, T., Curnutte, J. T., and Bokoch, G. M. (1991) Science 254, 1512-1515[Medline] [Order article via Infotrieve]
  8. Abo, A., Pick, E., Hall, A., Totty, N., Teahan, C. G., and Segal, A. W. (1991) Nature 353, 668-670[CrossRef][Medline] [Order article via Infotrieve]
  9. Heyworth, P. G., Knaus, U. G., Xu, X., Uhlinger, D. J., Conroy, L., Bokoch, G. M., and Curnutte, J. T. (1993) Mol. Biol. Cell 4, 261-269[Abstract]
  10. Abo, A., Boyhan, A., West, I., Thrasher, A. J., and Segal, A. W. (1992) J. Biol. Chem. 267, 16767-16770[Abstract/Free Full Text]
  11. Dorseuil, O., Vazquez, A., Lang, P., Bertoglio, J., Gacon, G., and Leca, G. (1992) J. Biol. Chem. 267, 20540-20542[Abstract/Free Full Text]
  12. Voncken, J. W., Schaick, H. V., Kaartinen, V., Deemer, K., Coates, T., Landing, B., Pattengale, P., Dorseuil, O., Bokoch, G. M., Groffen, J., and Heisterkamp, N. (1995) Cell 80, 719-728[Medline] [Order article via Infotrieve]
  13. Diekmann, D., Abo, A., Johnston, C., Segal, A. W., and Hall, A. (1994) Science 265, 531-533[Medline] [Order article via Infotrieve]
  14. Heyworth, P. G., Bohl, B. P., Bokoch, G. M., and Curnutte, J. T. (1994) J. Biol. Chem. 269, 30749-30752[Abstract/Free Full Text]
  15. Freeman, J. L., Kreck, M. L., Uhlinger, D. J., and Lambeth, J. D. (1994) Biochemistry 33, 13431-13435[Medline] [Order article via Infotrieve]
  16. Zigmond, S. H., Joyce, M., Borleis, J., Bokoch, G. M., and Devreotes, P. N. (1997) J. Cell Biol. 138, 363-374[Abstract/Free Full Text]
  17. Laudanna, C., Campbell, J. J., and Butcher, E. C. (1996) Science 271, 981-983[Abstract]
  18. Allen, W. E., Zicha, D., Ridley, A. J., and Jones, G. E. (1998) J. Cell Biol. 141, 1147-1157[Abstract/Free Full Text]
  19. Cox, D., Chang, P., Zhang, Q., Reddy, P. G., Bokoch, G. M., and Greenberg, S. (1997) J. Exp. Med. 186, 1487-1494[Abstract/Free Full Text]
  20. Massol, P., Montcourrier, P., Guillemot, J. C., and Chavrier, P. (1998) EMBO J. 17, 6219-6229[Abstract/Free Full Text]
  21. Hammond, S. M., Jenco, J. M., Nakashima, S., Cadwallader, K., Gu, Q., Cook, S., Nozawa, Y., Prestwich, G. D., Frohman, M. A., and Morris, A. J. (1997) J. Biol. Chem. 272, 3860-3868[Abstract/Free Full Text]
  22. Siddiqi, A. R., Smith, J. L., Ross, A. H., Qiu, R. G., Symons, M., and Exton, J. H. (1995) J. Biol. Chem. 270, 8466-8473[Abstract/Free Full Text]
  23. Houle, M. G., and Bourgoin, S. (1996) Biochem. Cell Biol. 74, 459-467[Medline] [Order article via Infotrieve]
  24. Knaus, U. G., Morris, S., Dong, H.-J., Chernoff, J., and Bokoch, G. M. (1995) Science 269, 221-223[Medline] [Order article via Infotrieve]
  25. Manser, E., Leung, T., Salihuddin, H., Zhao, Z.-S., and Lim, L. (1994) Nature 367, 40-46[CrossRef][Medline] [Order article via Infotrieve]
  26. Ahmed, S., Prigmore, E., Govind, S., Veryard, C., Kozma, R., Wientjes, F. B., Segal, A. W., and Lim, L. (1998) J. Biol. Chem. 273, 15693-15701[Abstract/Free Full Text]
  27. Burbelo, P. D., Dreschsel, D., and Hall, A. (1995) J. Biol. Chem. 270, 29071-29074[Abstract/Free Full Text]
  28. Leonard, D. A., Satoskar, R. S., Wu, W. J., Bagrodia, S., Cerione, R. A., and Manor, D. (1997) Biochemistry 36, 1173-1180[CrossRef][Medline] [Order article via Infotrieve]
  29. Thompson, G., Owen, D., Chalk, P. A., and Lowe, P. N. (1998) Biochemistry 37, 7885-7891[CrossRef][Medline] [Order article via Infotrieve]
  30. Knaus, U. G., Wang, Y., Reilly, A. M., Warnock, D., and Jackson, J. H. (1998) J. Biol. Chem. 273, 21512-21518[Abstract/Free Full Text]
  31. Badwey, J. A., Curnutte, J. T., Berde, C. B., and Karnovsky, M. L. (1982) Biochem. Biophys. Res. Commun. 106, 170-174[Medline] [Order article via Infotrieve]
  32. Prossnitz, E. R., Quehenberger, O., Cochrane, C. G., and Ye, R. D. (1993) J. Immunol. 151, 5704-5715[Abstract/Free Full Text]
  33. Knaus, U. G., Heyworth, P. G., Kinsella, B. T., Curnutte, J. T., and Bokoch, G. M. (1992) J. Biol. Chem. 267, 23575-23582[Abstract/Free Full Text]
  34. Quinn, M. T., Evans, T., Loetterle, L. R., Jesaitis, A. J., and Bokoch, G. M. (1993) J. Biol. Chem. 268, 20983-20987[Abstract/Free Full Text]
  35. Chuang, T. H., Xu, X., Knaus, U. G., Hart, M. J., and Bokoch, G. M. (1993) J. Biol. Chem. 268, 775-778[Abstract/Free Full Text]
  36. Bokoch, G. M., and Prossnitz, V. (1992) J. Clin. Invest. 89, 402-408[Medline] [Order article via Infotrieve]
  37. Bokoch, G. M., and Gilman, A. G. (1984) Cell 39, 301-308[Medline] [Order article via Infotrieve]
  38. Dorseuil, O., Quinn, M. T., and Bokoch, G. M. (1995) J. Leukocyte Biol. 58, 108-113[Abstract]
  39. Ptasznik, A., Traynor-Kaplan, A., and Bokoch, G. M. (1995) J. Biol. Chem. 270, 19969-19973[Abstract/Free Full Text]
  40. Hawkins, P. T., Eguinou, A., Qiu, R.-G., Stokoe, D., Cooke, F. T., Walters, R., Wennström, S., Claesson-Welsh, L., Evans, T., Symons, M., and Stephens, L. (1995) Curr. Biol. 5, 393-403[Medline] [Order article via Infotrieve]
  41. Baggiolini, M., Dewald, B., Schnyder, J., Ruch, W., Cooper, P. H., and Payne, T. G. (1987) Exp. Cell Res. 169, 408-418[Medline] [Order article via Infotrieve]
  42. Arcaro, A., and Wymann, M. P. (1993) Biochem. J. 296, 297-301[Medline] [Order article via Infotrieve]
  43. Okada, T., Sakuma, L., Fukui, Y., Hazeki, O., and Ui, M. (1994) J. Biol. Chem. 269, 3563-3567[Abstract/Free Full Text]
  44. Vlahos, C. J., Matter, W. F., Brown, R. F., Traynor-Kaplan, A. E., Heyworth, P. G., Prossnitz, E. R., Ye, R. D., Marder, P., Schelm, J. A., Rothfuss, K. J., Serlin, B. S., and Simpson, P. J. (1995) J. Immunol. 154, 2413-2422[Abstract/Free Full Text]
  45. Ptasznik, A., Prossnitz, E. R., Yoshikawa, D., Smrcka, A., Traynor-Kaplan, A. E., and Bokoch, G. M. (1996) J. Biol. Chem. 271, 25204-25207[Abstract/Free Full Text]
  46. Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweis, P. C., and Hawkins, P. T. (1994) Cell 77, 83-93[Medline] [Order article via Infotrieve]
  47. Bokoch, G. M., Bohl, B. P., and Chuang, T. H. (1994) J. Biol. Chem. 269, 31674-31679[Abstract/Free Full Text]
  48. Heyworth, P. G., Knaus, U. G., Settleman, J., Curnutte, J. T., and Bokoch, G. M. (1993) Mol. Biol. Cell 4, 1217-1223[Abstract]
  49. Crespo, P., Schuebel, K. E., Ostrom, A. A., Gutkind, J. S., and Busteol, X. R. (1997) Nature 385, 169-172[CrossRef][Medline] [Order article via Infotrieve]
  50. Han, J., Luby-Phelps, K., Das, B., Shu, X., Xia, Y., Mosteller, R. D., Krishna, U. M., Falck, J. R., White, M. A., and Broek, D. (1998) Science 279, 558-560[Abstract/Free Full Text]
  51. Katzav, S., Martin-Zanca, D., and Barbacid, M. (1989) EMBO J. 8, 2283-2290[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.